Featured Research

from universities, journals, and other organizations

Romosozumab significantly increases bone mineral density and bone content compared with teriparatide

Date:
June 11, 2014
Source:
European League Against Rheumatism
Summary:
A new study shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also compared with the commonly prescribed anabolic agent teriparatide and placebo.

A new study presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) shows that in postmenopausal women with low bone mass, romosozumab significantly increased bone mineral density and bone content in both the spine and hip compared to baseline, and also compared with the commonly prescribed anabolic agent teriparatide and placebo.

Related Articles


Romosozumab, administered subcutaneously at monthly intervals over a period of 12 months, resulted in gains in both the trabecular and cortical compartments of the spine and hip regions, with important differences between romosozumab and teriparatide observed depending on the skeletal location.

"These impressive results support the continued clinical investigation of romosozumab as a potential treatment for postmenopausal women with osteoporosis with established bone mineral density deficit who are at increased risk of fracture," said lead investigator Professor Harry K. Genant of the University of California San Francisco, and a Co-founder of Synarc, Inc. the world's largest imaging core lab dedicated to clinical trials.

"A large phase III clinical trial program is underway, evaluating romosozumab against both placebo and an active comparator in more than 10,000 women with postmenopausal osteoporosis to evaluate its potential to prevent osteoporotic fractures, and to confirm its safety for long-term use," Professor Genant added.

In the lumbar spine, treatment with romosozumab and teriparatide achieved similar and significant gains from baseline in trabecular bone mineral density +18.3% vs. +20.1% respectively p<0.05).

However, at the hip, trabecular bone mineral density gains were significantly larger with romosozumab than teriparatide (10.8% vs 4.2%, P=0.01). Cortical bone mineral density gains were larger with romosozumab compared with teriparatide at both the lumbar spine (13.7% vs. 5.7%, P<0.0001) and hip. Cortical bone mineral content gains were also larger with romosozumab compared with teriparatide at both the lumbar spine (23.3% vs. 10.9%, P<0.0001) and hip (3.4% vs. 0.0%, P=0.03).

Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. Romosozumab, a monoclonal antibody which binds to sclerostin, stimulates bone formation and decreases bone resorption.

"Because the gene that encodes sclerostin is primarily expressed in skeletal tissue, sclerostin inhibition provides an attractive mechanism of action. More precise targeting should limit the range of side effects, thereby offering a promising new approach to the treatment of post-menopausal osteoporosis," explained Professor Genant.

"The use of teriparatide, an effective anabolic agent which can stimulate bone growth and reduce the risk of fractures, is potentially problematic due to the requirement for daily subcutaneous injection, its relatively high cost, and also a black-box warning about the risk of inducing osteosarcoma in rats," Professor Genant concluded.

Post-menopausal osteoporosis is considered a serious public health concern due to its high prevalence worldwide. Approximately 30% of all postmenopausal women have osteoporosis in Europe and the US; at least 40% of these women will go on to sustain one or more fragility fractures in their lifetime.

The most common fractures associated with post-menopausal osteoporosis occur at the hip, spine and wrist.3 Of particular concern are vertebral (spinal) and hip fractures. Vertebral fractures can result in intense back pain and deformity. A hip fracture usually requires surgery and may result in loss of independence, or even death in an elderly frail patient.


Story Source:

The above story is based on materials provided by European League Against Rheumatism. Note: Materials may be edited for content and length.


Cite This Page:

European League Against Rheumatism. "Romosozumab significantly increases bone mineral density and bone content compared with teriparatide." ScienceDaily. ScienceDaily, 11 June 2014. <www.sciencedaily.com/releases/2014/06/140611093711.htm>.
European League Against Rheumatism. (2014, June 11). Romosozumab significantly increases bone mineral density and bone content compared with teriparatide. ScienceDaily. Retrieved December 20, 2014 from www.sciencedaily.com/releases/2014/06/140611093711.htm
European League Against Rheumatism. "Romosozumab significantly increases bone mineral density and bone content compared with teriparatide." ScienceDaily. www.sciencedaily.com/releases/2014/06/140611093711.htm (accessed December 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, December 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins